Stock Analiz

Serina Therapeutics, Inc. SER

Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026

$1.39Market cap $35M
Open the interactive analysis →

Serina Therapeutics, Inc. (SER) is a healthcare company listed in the US with a market value of about $35M. In the twelve months to September 30, 2026 it had revenue of $255000 and net income of -$24M, a net margin of -9606.3%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -18% a year, a 5-year average ROIC of -638%.

About Serina Therapeutics

Serina Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2018. Revenue went from $1M in 2017 to $130000 in 2025, a decline of about 25.7% a year. It was profitable in 1 of the last 9 years in our data. Its share count rose by 39% over three years (dilution for shareholders). It spends 10119% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth3/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Strong R&D investment or growth above 20%
  • ROE above 15%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S138.5
P/B2.5
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-64.7%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)132.1%
Revenue growth (5 yrs, per year)-18.5%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-14255.6%
ROIC (5-yr avg.)-637.5%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 9 years

Fiscal yearTTM202520242023202220212020201920182017
Revenue$255000$130000$56000$3M$34000$144000$361000$2M$1M$1M
Net income-$24M-$19M-$11M$5M-$10M-$9M-$11M-$12M-$8M-$7M
Free cash flow-$23M-$18M-$17M-$3M——-$8M-$11M-$8M-$6M
EPS (diluted)$-1.75$-1.91$-1.51$0.73$-0.00$-0.00$-0.00$-0.00$-0.00$-0.00
Net margin-9606.3%-14755.4%-19894.6%167.1%-30770.6%-6024.3%-3009.7%-703.4%-537.4%-468.7%
ROIC—-577.5%-1548.4%-0.2%-604.2%-457.4%—-375.0%-119.3%-72.3%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 2 analysts is $9.50, 583% above the current price; targets range from $8.00 to $11.00; the consensus rating is “none”; expected EPS is $-1.58 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Serina Therapeutics pay a dividend?

Not currently.

Is Serina Therapeutics a good stock to buy?

We do not give buy or sell advice. Serina Therapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.